Biliary Tract Cancer Treatment Market is projected to witness substantial growth over the next few years, driven by advancements in treatment modalities and increasing awareness of the condition. The pipeline for Biliary Tract Cancer Therapeutics includes promising candidates that aim to not only treat acute attacks but also prevent recurrence.

 

DelveInsight’s “Biliary Tract Cancer Market Insights, Epidemiology and Market Forecast – 2034” report delivers an in-depth understanding of the Biliary Tract Cancer, historical and forecasted epidemiology as well as the Biliary Tract Cancer market trends in the United States, EU4 (Germany, Spain, Italy, and France) and the United Kingdom, and Japan.

 

Unlock detailed insights into the Biliary Tract Cancer Market by downloading the comprehensive report from DelveInsight @ Biliary Tract Cancer Treatment Market Size

 

Key Takeaways from the Biliary Tract Cancer Market Report

• In September 2024:- AstraZeneca- A Phase IIIb, Single Arm, Open-label, Multicentre Study of Durvalumab in Combination With Chemotherapy for the First Line Treatment for Patients With Advanced Biliary Tract Cancers (TOURMALINE). A study to assess the safety and efficacy of durvalumab in combination with gemcitabine-based chemotherapy regimens in participants with aBTC.
• In September 2024:- Akeso- This is a phase 3 study. All subjects are patients with unresectable locally advanced or metastatic biliary tract cancer (BTC), Eastern Cooperative Oncology Group (ECOG) performance status 0-1. The purpose of this study is to evaluate the efficacy and safety of AK112 in combination with chemotherapy versus durvalumab in combination with chemotherapy in patients with unresectable locally advanced or metastatic BTC.
• As per the American Cancer Society, in 2018, there were 12,190 diagnoses cases of the gallbladder and extrahepatic bile duct cancer in the US. As per estimates, there were around 11,980 newly diagnosed cases for gallbladder and bile duct cancers in the US in 2020.
• GLOBOCAN database was explored for EU4 and the UK, wherein the incident cases for gallbladder cancers (GBC) were estimated. In 2020, in EU4 and the UK region, Germany had the highest number of GBC cases with 1,661 cases, followed by United Kingdom having 1,343 cases and the lowest number of cases were found in Spain i.e., 707 cases.
• In 2023, other biliary tract cancers represented the largest number of cases, approximately 24,000, followed by gallbladder cancer among BTC types by tumor location in the 7MM.
• The leading Biliary Tract Cancer Companies such as Incyte Corporation, Loxo Oncology, Bayer, Roche, Genentech, QED Therapeutics, Agios Pharmaceuticals, Servier Pharmaceuticals, Merck Sharp & Dohme, AstraZeneca, Taiho Oncology, Delcath Systems, Eisai, TransThera Sciences (Nanjing), Basilea Pharmaceutica, Zymeworks, BeiGene and others.
• Promising Biliary Tract Cancer Therapies such as PEMAZYRE (pemigatinib), ROZLYTREK (entrectinib), VITRAKVI (larotrectinib), TIBSOVO (ivosidenib), LYTGOBI (futibatinib), KEYTRUDA (pembrolizumab), IMFINZI (durvalumab), TAFINLAR (dabrafenib) + MEKINIST (trametinib), and others.

 

Gain a competitive edge in the Biliary Tract Cancer Market by exploring our in-depth analysis. Visit our website to access the full report and make informed strategic decisions @ Biliary Tract Cancer Treatment Drugs

 

Biliary Tract Cancer Epidemiology Segmentation in the 7MM

• Total Biliary Tract Cancer Incident Cases
• Biliary Tract Cancer Age-specific Cases
• Biliary Tract Cancer Stage-specific Cases
• Total Incident Cases of Biliary Tract Cancer by tumor location
• Biliary Tract Cancer Mutation-specific Cases
• Biliary Tract Cancer Treated Cases

 

Biliary Tract Cancer Treatment Market

Treatment options for the early-stage disease include surgery, followed by adjuvant chemotherapy. For patients with locally advanced disease, loco-regional therapies (e.g., trans-arterial chemoembolization [TACE] and external beam radiation therapy [EBRT]) may be considered. For patients with locally advanced and metastatic disease, the combination of gemcitabine and cisplatin has been shown to improve survival. Next-generation sequencing has identified somatic mutations in oncogenes (i.e., KRAS), tumor suppressors (i.e., TP53 and SMAD4), and chromatin-modifying genes (i.e., ARID1A, BAP1, and PBMR1) in BTC. Genetic alterations in the IDH1/2, BAP1, and FGFR2 are mostly restricted to intrahepatic CCAs (iCCAs), whereas mutations in KRAS and SMAD4 are more commonly observed in extrahepatic CCAs (eCCAs).

 

Discover key developments and opportunities in the Biliary Tract Cancer Market. Click here to learn more from DelveInsight’s latest report @ Biliary Tract Cancer Market Size

 

Biliary Tract Cancer Marketed Therapies

• PEMAZYRE (pemigatinib): Incyte
• IMFINZI (durvalumab): AstraZeneca

 

Biliary Tract Cancer Emerging Therapies

• CTX-009: Compass Therapeutics
• Zanidatamab: Jazz Pharmaceuticals/Zymeworks

 

Biliary Tract Cancer Market Outlook

Bile duct cancer begins when healthy cells in the bile duct change and grow out of control, forming a mass called a tumor. A tumor can be benign or cancerous. A benign tumor can grow but will not spread. A cancerous tumor is malignant, meaning it can grow and spread to other parts of the body. Treatment options for the early-stage disease include surgery, followed by adjuvant chemotherapy. For patients with locally advanced and metastatic disease, the combination of gemcitabine and cisplatin has been shown to improve survival. Potential therapies are being investigated for treating Biliary Tract Cancer. Even though it is too soon to comment on the above-mentioned promising candidate to enter the Biliary Tract Cancer market during the forecast period (2024–2034), it is safe to assume that the future of this market is promising. Eventually, the drugs, if approved, shall create a significant difference in the landscape of Biliary Tract Cancer in the coming years. The treatment space is expected to experience a significant impact in the coming years, owing to the increase in healthcare spending worldwide.

 

Download DelveInsight’s Biliary Tract Cancer Market report today and stay ahead in this rapidly evolving field. @ Biliary Tract Cancer Clinical Trials

 

Scope of the Biliary Tract Cancer Market Report

• Coverage- 7MM
• Biliary Tract Cancer Companies- Incyte Corporation, Loxo Oncology, Bayer, Roche, Genentech, QED Therapeutics, Agios Pharmaceuticals, Servier Pharmaceuticals, Merck Sharp & Dohme, AstraZeneca, Taiho Oncology, Delcath Systems, Eisai, TransThera Sciences (Nanjing), Basilea Pharmaceutica, Zymeworks, BeiGene and others.
• Biliary Tract Cancer Therapies- PEMAZYRE (pemigatinib), ROZLYTREK (entrectinib), VITRAKVI (larotrectinib), TIBSOVO (ivosidenib), LYTGOBI (futibatinib), KEYTRUDA (pembrolizumab), IMFINZI (durvalumab), TAFINLAR (dabrafenib) + MEKINIST (trametinib), and others.
• Biliary Tract Cancer Competitive Intelligence Analysis: SWOT analysis and Market entry strategies
• Biliary Tract Cancer Unmet Needs, KOL’s views, Analyst’s views, Biliary Tract Cancer Market Access and Reimbursement

 

Download the report to understand which factors are driving Biliary Tract Cancer Market Trends @ Biliary Tract Cancer Market Trends

 

Table of Content

1. Key Insights

2. Report Introduction

3. Executive Summary of Biliary Tract Cancer (BTC)

4. Key Events

5. Biliary Tract Cancer Market Overview at a Glance

6. Disease Background and Overview

7. Current Treatment Practices of Biliary Tract Cancer

8. Guidelines: Diagnosis and Treatment

9. Biliary Tract Cancer Epidemiology and Market Forecast Methodology

10. Biliary Tract Cancer Epidemiology and Patient Population

11. Biliary Tract Cancer Patient Journey

12. Marketed Biliary Tract Cancer Therapies

13. Emerging Biliary Tract Cancer Therapies

14. Biliary Tract Cancer (BTC) Market Analysis

15. Biliary Tract Cancer Unmet Needs

16. Biliary Tract Cancer SWOT Analysis

17. KOL Views

18. Biliary Tract Cancer Market Access and Reimbursement

19. Biliary Tract Cancer Market Access and Reimbursement

20. Appendix

21. DelveInsight Capabilities

22. Disclaimer

23. About DelveInsight

 

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 9650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/